BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:cagrilintide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of cagrilintide\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07411560-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270126
DTEND;VALUE=DATE:20270127
SUMMARY:cagrilintide: Phase 1 readout est. (NCT07411560)
DESCRIPTION:cagrilintide\, phase 1\, Obesity.\nStudy: A Study Looking at Ho
 w Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-rela
 ted Side Effects in People Who Are Overweight or Obese\nEstimated primary 
 completion: 26 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/cagrilintide#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07411560
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07557953-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270413
DTEND;VALUE=DATE:20270414
SUMMARY:cagrilintide: Phase 1 readout est. (NCT07557953)
DESCRIPTION:cagrilintide\, phase 1\, Obesity.\nStudy: A Research Study Look
 ing Into How Cagrilintide Influences Food Intake and Appetite in People Wi
 th Overweight or Obesity\nEstimated primary completion: 13 April 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07557953
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220642-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270511
DTEND;VALUE=DATE:20270512
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220642)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity Following Treatment With Cagrilintide\n
 Estimated primary completion: 11 May 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/cagrilintide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07220642
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220759-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220759)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity and Type 2 Diabetes Following Treatment
  With Cagrilintide\nEstimated primary completion: 12 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220759
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07745504-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270518
DTEND;VALUE=DATE:20270519
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07745504)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study to C
 ompare Two Different Versions of Injectable Cagrilintide and Placebo in Pe
 ople With Excess Body Weight\nEstimated primary completion: 18 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07745504
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07597018-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:cagrilintide: Phase 1 readout est. (NCT07597018)
DESCRIPTION:cagrilintide\, phase 1\, Obesity.\nStudy: A Research Study to C
 ompare Blood Levels of Cagrilintide After Multiple Doses of Different Vers
 ions of Cagrilintide in Adults With Overweight or Obesity\nEstimated prima
 ry completion: 28 May 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/cagrilintide#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07597018
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07607587-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20271119
DTEND;VALUE=DATE:20271120
SUMMARY:cagrilintide: Phase 1 readout est. (NCT07607587)
DESCRIPTION:cagrilintide\, phase 1\, Obesity.\nStudy: Evaluation of the Tol
 erability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapie
 s Due to Gastrointestinal Adverse Events\nEstimated primary completion: 19
  November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cagri
 lintide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07607587
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527195-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20280428
DTEND;VALUE=DATE:20280429
SUMMARY:cagrilintide: Phase 1 readout est. (NCT07527195)
DESCRIPTION:cagrilintide\, phase 1\, Obesity.\nStudy: Understanding the Eff
 ect of CagriSema\, Cagrilintide\, and Semaglutide on Muscle Health (Role o
 f Amylin Signature in Muscle Health)\nEstimated primary completion: 28 Apr
 il 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT075
 27195
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010432-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20280503
DTEND;VALUE=DATE:20280504
SUMMARY:cagrilintide: Phase 1 readout est. (NCT07010432)
DESCRIPTION:cagrilintide\, phase 1\, Obesity.\nStudy: The Role of the Amyli
 n Analogue Cagrilintide in Bone Metabolism\nEstimated primary completion: 
 3 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cagrilint
 ide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07010432
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07253285-120@assetmemo.bio
DTSTAMP:20261121T005424Z
DTSTART;VALUE=DATE:20300320
DTEND;VALUE=DATE:20300321
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07253285)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: A Research Study on H
 ow Well Cagrilintide and CagriSema Work in Children and Adolescents With E
 xcess Body Weight\nEstimated primary completion: 20 March 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07253285
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
